Peer-reviewed Publications
Champions Oncology Authored Publications
Cells: Alternative Splicing of RAD6B and Not RAD6A Is Selectively Increased in Melanoma: Identification and Functional Characterization
November 2019
Oncotarget: Volasertib preclinical activity in high-risk hepatoblastoma
November 2019
Sci Signal: The HDAC3-SMARCA4-miR27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
May 2019
Cancer Research: PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
November 2017
Annals of Oncology: Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
October 2017
British Journal of Cancer: Comparative mutational landscape analysis of patient-derived tumour xenografts
January 2017
Clinical Cancer Research: Screening of conditionally reprogrammed patient-derived carcinoma cells identified ERCC3-MYC interactions as a target in pancreatic cancer
December 2016
Cancer: Patient-derived xenografts for individualized care in advanced sarcoma
July 2014
Clinical Cancer Research: Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
May 2014
Journal of Clinical Oncology: Prioritizing phase I treatment options through preclinical testing on personalized TumorGraft
February 2012
Publications Using Champions Oncology’s TumorGraft Models
The PSMA Targeting Half-Life Extended BiTE ® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer
January 2021
American Association for Cancer Research: 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
January 2021
British Journal of Cancer: SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
December 2020
Cell: Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids
June 2020
Molecular Cancer Therapeutics: Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
April 2020
Molecular Cancer Therapeutics: ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
February 2020
Breast Cancer Research: Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
December 2019
Oncogene: Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
November 2019
Nature Communications: AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
November 2019
Nature Communications: The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
August 2019
